John Mattingly
Hematology & Oncology · Portsmouth, VANPI 1922327907
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 96.3% of the total across 54 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 24 manufacturers, the largest accounting for just 19.6% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2022 at $528 and has fallen 68.8% since, to $165 in 2025. That places this record below the midpoint for hematology & oncology clinicians in VA, where the typical reported total is $1,232.
Across 54 payments — averaging $21.91 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$232
- Karyopharm Therapeutics Inc.$84
- Incyte Corporation$84
- E.r. Squibb & Sons, L.L.C.$80
- Bristol Myers Squibb$69
- G1 Therapeutics, Inc.$66
- plus $568 from 18 others
What the payments were for
- Food & beverage$1,14096%
- Education$434%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca(2 entities) | 10 | $232 |
| Karyopharm Therapeutics Inc. | 4 | $84 |
| Incyte Corporation | 5 | $84 |
| E.r. Squibb & Sons, L.L.C. | 2 | $80 |
| Bristol Myers Squibb | 3 | $69 |
| G1 Therapeutics, Inc. | 3 | $66 |
| GSK | 3 | $62 |
| Exelixis Inc. | 3 | $58 |
| AbbVie | 2 | $53 |
| Mirati Therapeutics, Inc. | 2 | $50 |
| Stemline Therapeutics Inc. | 2 | $38 |
| Johnson & Johnson | 2 | $36 |
| CTI Biopharma Corp. | 2 | $34 |
| Tersera Therapeutics LLC | 1 | $26 |
| Ipsen Biopharmaceuticals, Inc | 1 | $24 |
| Merck | 1 | $24 |
| AVEO Pharmaceuticals, Inc. | 1 | $24 |
| Seagen Inc. | 1 | $24 |
| Rigel Pharmaceuticals, Inc. | 1 | $23 |
| ADC Therapeutics America, Inc. | 1 | $22 |
| Morphosys, US Inc. | 1 | $21 |
| Novocure Inc. | 1 | $19 |
| Amgen | 1 | $16 |
| Boehringer Ingelheim | 1 | $14 |
How this compares
$1,183 in reported general payments places this provider in the 45th percentile of 293 hematology & oncology providers in Virginia.
Other hematology & oncology in Portsmouth
- Lloyd ShabazzPortsmouth$16K
- Ruby KochharHampton$236K
- Victor YazbeckRichmond$190K
- David ChangNewport News$141K
- William ErshlerFairfax$139K
- Yue ZhangVirginia Beach$105K
- Jerome GoldschmidtChristiansburg$105K
- Attique SamdaniRichmond$104K
- Gary SimmonsNorfolk$82K
- Mark FlemingHampton$71K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.